¹Ì±¹ÀÇ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå - ±¹°¡º° ºÐ¼® : ¹ÙÀÌ¿À¸¶Ä¿ À¯Çüº°, ¾Ï À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ºÐ¼®°ú ¿¹Ãø(2025-2035³â)
U.S. Prostate Cancer Testing Market - A Country Analysis: Focus on Type of Biomarker, Cancer Type, Application, End User, and Region - Analysis and Forecast, 2025-2035
»óǰÄÚµå : 1711584
¸®¼­Ä¡»ç : BIS Research Inc.
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,900 £Ü 6,953,000
PDF and Excel (1-3 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,643,000
PDF and Excel (Global License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹Ì±¹ÀÇ Àü¸³¼±¾Ï °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº ¾Ï¿¬±¸ ºÐ¾ß¿¡ ´ëÇÑ °í¾×ÀÇ ÅõÀÚ¿Í ¹Ì±¹¿¡¼­ Àü¸³¼±¾ÏÀÇ À¯º´·ü »ó½Â¿¡ ÀÇÇØ ÃËÁøµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¶ÇÇÑ ºñÁî´Ï½º ¸®´õÀÇ ÃÊÁ¡Àº ¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀåÀ» ÀÌÇØÇϱâ À§ÇØ ÀÓ»ó ¿¬±¸ÀÇ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÇØ°áÇϱâ À§ÇØ ÀÓ»ó ¿¬±¸¿¡ ´ëÇÑ ±íÀº ÀÌÇØ¸¦ È®¸³ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

¹Ì±¹ Àü¸³¼±¾Ï °ËÁø ½ÃÀåÀº ¹ßÀü ´Ü°è¿¡ ÀÖ½À´Ï´Ù. ÀÏ¹Ý Àα¸¿¡¼­ PSA °Ë»ç ¶Ç´Â PSA °Ë»ç´Â Áö³­ ¼ö½Ê³â°£ Àü¸³¼±¾Ï ¹ß»ý·üÀ» Áõ°¡½ÃÄ×½À´Ï´Ù. ¶ÇÇÑ Àü¸³¼±¾Ï °Ë»ç´Â ¸ÂÃãÇü Ä¡·áÀÇ ¾ÈÀüÇÏ°í ¼º°øÀûÀÎ Ä¡·á¸¦ º¸ÀåÇϱâ À§ÇØ Á¤¹ÐÀÇ·á¿¡¼­ ÇʼöÀûÀÔ´Ï´Ù. ¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå¿¡ ÁøÃâÇÑ ´ëºÎºÐÀÇ ¾÷üµéÀº ¼Òº¯, Ç÷¾×, Á¶Á÷ ±â¹ÝÀÇ ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç ¹× °Ë»ç ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Àü¸³¼±¾Ï °Ë»çÀÇ ¿ëµµ´Â ÁÖ·Î ÀÓ»ó ¹× ¿¬±¸¿ëÀÔ´Ï´Ù.

¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀåÀÌ ÇâÈÄ ¼ö³â°£ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ÀÌÀ¯ Áß Çϳª´Â Àü¸³¼±¾Ï ȯÀÚ Áõ°¡ÀÔ´Ï´Ù. Àü¸³¼±¾ÏÀº ³²¼º¿¡¼­ µÎ ¹øÂ°·Î ³ôÀº ºóµµ·Î Áø´ÜµÇ´Â ÁúȯÀ̸ç, ±× ºóµµ´Â Àü ¼¼°è¿¡¼­ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ¸Å³â 100¸¸ °ÇÀÇ Àü¸³¼±¾ÏÀÌ Ãß°¡·Î Áø´ÜµÇ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. Àα¸ÀÇ °í·ÉÈ­, µµ½ÃÈ­ ¹× ±×¿¡ µû¸¥ ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­·Î ÀÎÇØ Àü¸³¼±¾ÏÀÇ Àü¹ÝÀûÀÎ ¹ß»ý·üÀº Áö³­ ¼ö½Ê³â°£ Áõ°¡ÇÏ¸ç ¿Ô½À´Ï´Ù.

¹ÙÀÌ¿À¸¶Ä¿ À¯Çüº°·Î´Â ¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå¿¡¼­ »ý°Ë Àü °Ë»ç´Â ¹ÙÀÌ¿À¸¶Ä¿ À¯Çü ºÐ·ù°¡ ¿ìÀ§¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â Àü¸³¼±¾Ï °Ë»çÀÇ ÀαⰡ ³ô¾ÆÁö°í Àü¸³¼±¾Ï °Ë»ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁ³±â ¶§¹®ÀÔ´Ï´Ù.

¾ÏÁ¾º°·Î´Â Àü¸³¼±¾ÏÀÌ ¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â Àü¸³¼±¾Ï ¹ßº´·ü Áõ°¡¿Í Àü¸³¼±¾Ï °Ë»çÀÇ ÀαⰡ ³ô¾ÆÁ³±â ¶§¹®ÀÔ´Ï´Ù.

¿ëµµº°·Î º¸¸é ¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀåÀº Àü¸³¼±¾Ï °Ë»ç °³¹ß¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸°³¹ß Ȱµ¿ Áõ°¡·Î ÀÎÇØ Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿ ºÎ¹®ÀÌ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Àü¸³¼±¾Ï Áø´ÜÀ» À§ÇØ ºÐÀÚ ±â¹ÝÀÇ »õ·Î¿î Áø´Ü ±â¼úÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. Áø´Ü½Ã ÀÓ»óÀûÀ¸·Î °ü·Ã¼ºÀÌ ÀÖ´Â ¾ÏÀ» ¹ß°ßÇϱâ À§Çؼ­´Â ȯÀÚÀÇ »îÀÇ ÁúÀ» °³¼±ÇÒ ¼ö ÀÖ´Â ¸î °¡Áö Åø¿Í Ä¡·á ¿É¼ÇÀÌ ÇÊ¿äÇÕ´Ï´Ù.

¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀåÀº ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) Áõ°¡·Î ÀÎÇØ ASC°¡ ¾ÐµµÀûÀÎ Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ASC´Â °Ë»ç ¹× º¸È£ Á¶Ä¡¸¦ Æ÷ÇÔÇÑ ¿Ü°úÀû Ä¡·á¸¦ ´çÀÏ¿¡ Á¦°øÇÏ´Â µ¥ Àü³äÇϰí ÀÖÀ¸¸ç, ¾çÁúÀÇ Ä¡·á¿Í ¼º°øÀûÀΠȯÀÚ °á°ú¸¦ Á¦°øÇϰí ȯÀڵ鿡°Ô º´¿ø ¿Ü·¡ ¼ö¼úº¸´Ù ´õ Æí¸®ÇÑ ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ¼ö¹é¸¸ ¸íÀÇ ¹Ì±¹ÀεéÀÇ ¿Ü·¡ °æÇèÀ» º¯È­½ÃÄÑ ¿Ô½À´Ï´Ù.

¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ

¿öÅ©Ç÷οì/Çõ½Å Àü·«: ¿öÅ©ÇÃ·Î¿ì ºÎ¹®Àº µ¶ÀÚµéÀÌ µÎ °¡Áö Àü¸³¼±¾Ï °Ë»ç, Áï ÃÊ±â Æò°¡: Àü¸³¼± ƯÀÌÇ׿ø(ÃÑ PSA, À¯¸® PSA), »ý°Ë Àü/»ý°Ë ÈÄ À½¼º °Ë»ç, »ý°Ë ÈÄ Á¶Á÷ °Ë»ç¿¡ ´ëÇÑ ÀÌÇØ¸¦ µ½°í, À̸¦ ÅëÇØ Áø´Ü¿¡ µµ¿òÀ» ÁÙ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¶ÇÇÑ ÀÌ Á¶»ç´Â µ¶Àڵ鿡°Ô ÀÓ»ó ¹× ¿¬±¸¿ë Àü¸³¼±¾Ï °Ë»çÀÇ ´Ù¾çÇÑ ÀÀ¿ë¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀÌÇØ¸¦ Á¦°øÇÕ´Ï´Ù.

¼ºÀå/¸¶ÄÉÆÃ Àü·«: Àü¸³¼±¾Ï °Ë»ç´Â ¿¬±¸¿Í ÀÓ»ó ÀÀ¿ë ¸ðµÎ¿¡¼­ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ±â¾÷ÀÌ Áø´Ü¿¡ µµ¿òÀÌ µÇ´Â ¼Òº¯, Ç÷¾×, Á¶Á÷ ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå ÁøÃâ±â¾÷ÀÌ ÇöÀç ¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå¿¡¼­ ¿ìÀ§¸¦ Á¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ Àü·«À̱⵵ ÇÕ´Ï´Ù.

°æÀï Àü·«: ÀÌ º¸°í¼­¿¡¼­´Â ½ÅÁ¦Ç° Ãâ½Ã, Àμö, »ç¾÷ È®Àå, Àü·«Àû Á¦ÈÞ µî ¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ¾÷üµéÀ» ºÐ¼®ÇÏ¿© ÇÁ·ÎÆÄÀϸµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå¿¡ ÁøÃâÇÑ ¾÷üµéÀÇ »ó¼¼ÇÑ °æÀï º¥Ä¡¸¶Å·À» ÅëÇØ µ¶Àڵ鿡°Ô ¸íÈ®ÇÑ ½ÃÀå »óȲÀ» Á¦½ÃÇϰí, ¾÷üµéÀÌ ¼­·Î ¾î¶»°Ô ¾ôÇôÀÖ´ÂÁö ÆÄ¾ÇÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¶ÇÇÑ Á¦ÈÞ, ÇÕÀÇ, Çù·Â°ú °°Àº Á¾ÇÕÀûÀÎ °æÀï Àü·«Àº µ¶ÀÚµéÀÌ ¹Ì±¹ Àü¸³¼±¾Ï ½ÃÀåÀÇ ¹Ì°³¹ß ¸ÅÃâ Æ÷ÄÏÀ» ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ ¹× °æÀï»ç ¿ä¾à

Àü¸³¼±¾Ï(PCa) ½ºÅ©¸®´× ±â¼úÀ» °­È­Çϱâ À§ÇØ PSA ¹× ±× µ¿Çüüº¸´Ù PCa ƯÀ̼ºÀÌ ³ôÀº »õ·Î¿î Àü¸³¼±¾Ï(PCa) ¹ÙÀÌ¿À¸¶Ä¿°¡ µîÀåÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿´Â °ËÃâ ¶Ç´Â Æò°¡¸¦ ÅëÇØ ±âÁ¸ÀÇ ÀÓ»óÀû Ư¡À» ³Ñ¾î Áúº´ÀÇ ¼¼ºÎ »çÇ×À» ¹àÇô³»´Â ºÐÀÚ¸¦ ¸»ÇÕ´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿´Â Ç÷¾×, ¼Òº¯, Á¶Á÷ »ùÇà µî ´Ù¾çÇÑ °÷¿¡ Á¸ÀçÇÕ´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿´Â Áø´Ü ¹× ¿¹ÈÄ µ¥ÀÌÅ͸¦ ¸ðµÎ Á¦°øÇÒ ¼ö ÀÖÀ¸¸ç, ÀÇ·á Àü¹®°¡°¡ °³º° Ä¡·á ¼±Åÿ¡ Á¤º¸¸¦ Á¦°øÇϱâ À§ÇÑ Áúº´ ¿¹ÃøÀ» ÇÒ ¶§ µµ¿òÀÌ µË´Ï´Ù. PSA °Ë»ç¸¦ Á¦¿ÜÇÑ ¹Ì±¹ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå(¹ÙÀÌ¿À¸¶Ä¿ À¯Çüº°)Àº »ý°Ë Àü/»ý°Ë ÈÄ À½¼º °Ë»ç¿Í »ý°Ë Àü/»ý°Ë ÈÄ Á¶Á÷ °Ë»ç·Î ±¸ºÐµË´Ï´Ù. ÈÄ Á¶Á÷°Ë»ç·Î ±¸ºÐµË´Ï´Ù.

¹Ì±¹ÀÇ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀåÀÇ °³¿ä¿Í ¹ÙÀÌ¿À¸¶Ä¿ À¯Çüº°, ¾Ï À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ ¹× ½ÃÀå¿¡ Âü¿©ÇÏ´Â ±â¾÷ÀÇ °³¿ä µîÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

°³¿ä

Á¦1Àå ½ÃÀå °³¿ä

Á¦2Àå ¾÷°è ºÐ¼®

Á¦3Àå ½ÃÀå ¿ªÇÐ

Á¦4Àå ¹Ì±¹ÀÇ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå : °æÀï ±¸µµ

Á¦5Àå ¹Ì±¹ÀÇ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå, ¹ÙÀÌ¿À¸¶Ä¿ À¯Çüº°, (100¸¸ ´Þ·¯), 2023-2035³â

Á¦6Àå ¹Ì±¹ÀÇ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå, ¾Ï À¯Çüº°, (100¸¸ ´Þ·¯), 2023-2035³â

Á¦7Àå ¹Ì±¹ÀÇ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå, ¿ëµµº°, (100¸¸ ´Þ·¯), 2023-2035³â

Á¦8Àå ¹Ì±¹ÀÇ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, (100¸¸ ´Þ·¯), 2023-2035³â

Á¦9Àå ¹Ì±¹ÀÇ Àü¸³¼±¾Ï °Ë»ç ½ÃÀå, Áö¿ªº°, (100¸¸ ´Þ·¯), 2023-2035³â

Á¦10Àå ±â¾÷ °³¿ä

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

U.S. Prostate Cancer Testing Market Industry Overview

The growth in the U.S. prostate cancer testing market is expected to be driven by high investments in the field of cancer research and the rising prevalence of prostate cancer in the U.S. In addition, the focus of business leaders is establishing a deep understanding to address the unmet needs in clinical research to understand the U.S. prostate cancer testing market.

Market Lifecycle Stage

The U.S. prostate cancer testing market is in the progressing phase. PSA screening or testing in a general population has increased the incidence of prostate cancer in recent decades. In addition, prostate cancer testing is essential in precision medicine because it assures the safe and successful use of tailored therapies. The majority of the companies in the U.S. prostate cancer testing market provide biomarker tests that are urine, blood, and tissue-based, as well as testing services. Furthermore, applications of prostate cancer testing are primarily clinical and research.

Impact

One of the main reasons for the expansion of the U.S. prostate cancer testing market in the upcoming years is the rise in prostate cancer cases. Prostate cancer is the second most frequent disease diagnosed in men, and its frequency is rising across the globe. Prostate cancer is thought to be diagnosed in one million additional cases worldwide each year. Due to an aging population, growing urbanization, and accompanying lifestyle changes, the overall incidence of prostate cancer has increased over the past few decades.

Market Segmentation:

Segmentation 1: by Biomarker Type

Based on biomarker type, the pre-biopsy test in the U.S. prostate cancer testing market is expected to be dominated by the biomarker type segment. This is due to the increasing popularity of prostate cancer testing and rising awareness related to prostate cancer testing.

Segmentation 2: by Cancer Type

Based on Cancer type, prostatic adenocarcinoma accounted for the largest share of the U.S. prostate cancer testing market. This is due to the increasing incidences of prostate cancer and increasing popularity of prostate cancer testing.

Segmentation 3: by Application

Based on application, the U.S. prostate cancer testing market is dominated by the diagnostics biomarkers segment owing to the rising R&D activity focused on the development of prostate cancer testing. The diagnosis of prostate cancer has developed a new molecular-based diagnostics technology. To detect clinically relevant cancer upon diagnosis, several tools or therapeutic options are required to improve the patient's quality of life.

Segmentation 4: by End User

Based on end user, the U.S. prostate cancer testing market is dominated by the ambulatory surgical centers (ASCs) segment owing to their rise in number. They are dedicated to offering same-day surgical care, including testing and protective procedures. ASCs, which have a proven track record of providing high-quality treatment and successful patient outcomes, have altered the outpatient experience for millions of Americans by giving patients a more convenient option for hospital-based outpatient operations.

Segmentation 5: by Region

Recent Developments in the U.S. Prostate Cancer Testing Market

Demand - Drivers and Limitations

The following are the demand drivers for the U.S. prostate cancer testing market:

The market is expected to face some limitations due to the following challenges:

How can this report add value to an organization?

Workflow/Innovation Strategy: The workflow segment helps the reader understand the two prostate cancer testing, i.e., initial evaluation: prostate-specific antigen (total PSA, free PSA), pre-biopsy/post-negative biopsy testing, and post-biopsy tissue testing, which further aid in diagnosis. Moreover, the study provides the reader with a detailed understanding of the different applications of prostate cancer testing in clinical and research applications.

Growth/Marketing Strategy: Prostate cancer testing is being used for both research and clinical application. Various companies are providing urine and blood, and tissue-based biomarkers that aid in the diagnosis, which is also the key strategy for U.S. prostate cancer testing market players to excel in the current U.S. prostate cancer testing market.

Competitive Strategy: Key players in the U.S. prostate cancer testing market are analyzed and profiled in the study, including manufacturers who are involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the U.S. prostate cancer testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the U.S. prostate cancer market.

Key Market Players and Competition Synopsis

A new wave of prostate cancer (PCa) biomarkers with greater PCa specificity than PSA and its isoforms have emerged to enhance PCa screening techniques. Biomarkers are molecules that, when detected or assessed, reveal details about a disease that goes beyond conventional clinical characteristics. They can be found in a number of places, including blood, urine, and tissue samples. Both diagnostic and prognostic data can be provided by biomarkers, supporting healthcare professionals in formulating illness projections intended to inform treatment choices on an individual basis. The U.S. prostate cancer testing market (by biomarker type) excluding PSA Tests is segmented into pre-biopsy/post-negative biopsy testing and post-biopsy tissue testing.

Some of the prominent names in the U.S. prostate cancer testing market are:

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

Research Methodology

1. Markets Overview

2. Industry Analysis

3. Market Dynamics

4. U.S. Prostate Cancer Testing Market: Competitive Landscape

5. U.S. Prostate Cancer Testing Market (by Biomarker Type), ($Million), 2023-2035

6. U.S. Prostate Cancer Testing Market (by Cancer Type), ($Million), 2023-2035

7. U.S. Prostate Cancer Testing Market (by Application), ($Million), 2023-2035

8. U.S. Prostate Cancer Testing Market (by End User), ($Million), 2023-2035

9. U.S. Prostate Cancer Testing Market (by Region), ($Million), 2023-2035

10. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â